Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer

Anticancer Research

Volumn 20, Issue 6 A, 2000, Pages 4097-4102

  Nakayama, Y ^a   Sako, T ^a   Shibao, K ^a   Onitsuka, K ^a   Nagashima, N ^a   Hirata, K ^a   Nagata, N ^a   Itoh, H ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Colorectal cancer; Interleukin 12; VEGF

Indexed keywords

INTERLEUKIN 12; VASCULOTROPIN;

ADULT; AGED; CLINICAL ARTICLE; COLON RESECTION; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; COLORECTAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERLEUKIN-12; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033637814     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. What is the evidence that tumors are angiogenesis dependent?
2. The biology of vascular endothelial growth factor
3. The fibroblast growth factor family
4. Tranforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor
5. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
6. Interleukin-8 as a macrophage-derived mediator of angiogenesis supresses tumor groeth in vivo
7. Pituitary follicular cells secrete a novel heparin-binding growth factor for vascular endothelial cells
8. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded throughg altenative exon splicing
9. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis
10. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer
11. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
12. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
13. Vessel counts and expression of vascular endothelial growth factor as prognostic factor in node-negative colon cancer
14. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells
15. Induction of TH1 and TH2 responses: A key role for the 'natural' immune response?
16. Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages stimulate IFN-gamma production is IFN-gamma-dependent
17. Antitumor and antimetastatic activity of interleukin-12 against routine tumors
18. Inhibition of cancer cell motility and invasion by IL- 12
19. Interleukin-12: A new clinical player in cytokine therapy
20. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL- 12
21. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
22. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation
23. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
24. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
25. Advanced colorectal cancer is associated with impaired Interleukin-12 and enhanced Interleukin-10 production
26. Interleukin-12 in early or advanced cancer patients
27. Serum levels of interleukin-12 in patients with the gastrointestinal cancer
28. IL- 12 regulates VEGF and MMPs in a murine breast cancer model
29. Serum vascular endothelial growth factor is often elevated in disseminated cancer
30. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients
31. Circulating vascular endothelial growth factor in patients with colorectal cancer
32. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
33. Platelet: Transporter of vascular endothelial growth factor
34. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
35. Interleukin-6 (IL-6)
36. Interleukin-10
37. The immunotherapy and gene therapy of cancer
38. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL- 12 genes
39. Amount of interleukin 12 available at the tumor site is critical for tumor regression
40. Human Th1 and Th2 cells: Functional properties, mechanism of regulation and role in disease
41. Functional evaluation of tumor-infiltrating mononuclear cells. Detection of endogenous interferon-γ and tumor necrosis factor-α in human colorectal adenocarcinomas
42. Decreased interleukin-2 production in patients with gastrointestinal cancer
43. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells
44. Inhibition of angiogenesis in vivo by interleukin 12
45. Multiple molecular and cellular changes associated with tumor stasis and regression during IL-12 therapy of a murine breast cancer model